Status:
UNKNOWN
Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy
Lead Sponsor:
Ruijin Hospital
Conditions:
Mild Non-proliferative Diabetic Retinopathy
Cataract Diabetic
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
Diabetic retinopathy has been found progress in 20-70% diabetic patient after cataract phacoemulsification surgery. Intravitreal injection of anti-VEGF Ranibizumab is an important treatment for diabet...
Detailed Description
This research is a single-center prospective, randomized controlled study. Patient were divided into two groups, the control group is phacoemulsification surgery group and the intervention group is ph...
Eligibility Criteria
Inclusion
- Signed and dated informed consent
- Commitment to follow the research procedures and cooperate with the implementation of the whole process of research
- No specific gender, 18+ years old
- Diagnosed in line with NPDR,
- Phacoemulsification combined with anti-VEGF therapy is planned
- No obvious surgical contraindications
Exclusion
- Use of other investigational drug treatments or take part in other types of clinical studies
- Allergy to anti-VEGF drugs
- Patients with other macular and optic disc diseases
- Patients with meaningful diabetic macular edema
- Patient with surgical complications
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2023
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT05386160
Start Date
July 1 2022
End Date
March 1 2023
Last Update
May 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Ophthalmology, Ruijin Hospital Affiliated Medical,Shanghai Jiaotong University School
Shanghai, Shanghai Municipality, China, 200025